Diederik Hentenaar

37 Biomarkers in crevicular peri-implant fluid significantly different outcomes (see Table 3a and 3b; the modConc column). Therefore, Luminex™ concentration outcomes in pg/ml per 30 seconds (see figure 1) were used for the assessment of biomarker levels in this study. At last, quantitative analysis of PICF showed a significant higher amount of PICF in diseased implants compared to healthy implants at baseline (Table 4). Chapter 2 Figure 1. Indicating changes in biomarker levels per 30-sec in pg/ml of IL-1  , IL6, TN 1  /CCL3, MMP-8, OPG and G-CSF between healthy control implants and diseased im T0) and after (PI T3) non-surgical peri-implantitis therapy. Significant differences bet represented as * (p- value ≤ 0.05). Figure 1. Indicating changes in biomarker levels per 30-sec in pg/ml of IL-1 β, IL6, TNF-α, MCP-1, MIP-1α/ CCL3, MMP-8, OPG and G-CSF between healthy control implants and diseased implants before (PI T0) and after (PI T3) non-surgical peri-implantitis therapy. Significant differences between groups are represented as * (p-value ≤ 0.05). 2